Every 10-Q that Edesa Biotech, Inc. (EDSA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow EDSA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EDSA filings page.
Edesa Biotech, Inc. reported larger losses for the quarter and nine months ended June 30, 2026 while advancing its inflammatory and immune‑related drug pipeline. Net loss was $5.4 million for the quarter and $11.9 million for the nine months, compared with $1.7 million and $5.0 million in the prior‑year periods, driven mainly by higher research and development spending on vitiligo candidate EB06 and respiratory candidate paridiprubart.
R&D expenses rose to $3.96 million in the quarter and $7.85 million year‑to‑date, while cash used in operating activities increased to $7.2 million for the nine months. Edesa ended the period with $10.3 million in cash and cash equivalents, working capital of $6.9 million, and an accumulated deficit of $77.9 million. The company disclosed a material uncertainty about its ability to continue as a going concern and expects existing resources, potential ATM sales, and Canadian SRF reimbursements will not fund operations, including the vitiligo program, through fiscal 2026 without additional financing.
Edesa highlighted progress in its pipeline, including regulatory readiness for a Phase 2 EB06 vitiligo study and prior positive Phase 3 data for paridiprubart in ARDS. It also benefits from up to C$23 million in partially repayable Canadian government Strategic Response Fund support and recently raised capital via ATM sales and a June 2026 private placement.
Edesa Biotech, Inc. reported a net loss of $4.2 million for the quarter and $6.5 million for the six months ended March 31, 2026, wider than the prior-year periods. Loss per share was $0.49 for the quarter and $0.78 year-to-date.
Research and development spending rose sharply to $2.8 million for the quarter and $3.9 million year-to-date, driven mainly by manufacturing and preparations for a Phase 2 vitiligo study (EB06) and readiness work for paridiprubart. General and administrative expenses also increased to $1.5 million for the quarter and $2.7 million for six months.
Edesa ended the period with $10.0 million in cash and cash equivalents and working capital of $8.2 million. Management discloses that existing cash, potential ATM share sales and Canadian government reimbursements are not expected to fund operations, including the vitiligo program, through fiscal 2026, creating a material going concern uncertainty and a need for additional financing.
Edesa Biotech, Inc. reported a net loss of $2.25 million for the quarter ended December 31, 2025, compared with a $1.62 million loss a year earlier. Research and development expenses rose to $1.12 million and general and administrative costs to $1.22 million, reflecting higher clinical and corporate activity.
The company ended the quarter with $12.1 million in cash and cash equivalents and working capital of $12.0 million, helped by $3.50 million of common share sales under its at-the-market program. Management cautions that there is a material uncertainty that may cast substantial doubt on its ability to continue as a going concern without additional funding.
Edesa is advancing EB06 for vitiligo toward a Phase 2 study and evaluating Phase 3 data for EB05 (paridiprubart) in acute respiratory distress syndrome, supported in part by up to C$23 million of Canadian government Strategic Response Fund backing.
Edesa Biotech, Inc. reported a strengthened liquidity position driven by private placements: cash and cash equivalents increased to $12.36 million at June 30, 2025 and working capital was approximately $12.1 million. For the nine months ended June 30, 2025 the company recorded a net loss of $4.96 million, contributing to an accumulated deficit of $63.65 million. The company received gross proceeds of about $15.0 million from a Series B-1 private placement and $1.54 million from a Series A-1 issuance.
The company continues clinical development across two programs: EB05 is participating in a BARDA-funded platform trial and EB06 is advancing toward a Phase 2 vitiligo study with manufacturing preparation underway. The Canadian Strategic Innovation Fund committed up to C$23 million (partially repayable) to support Phase 3 and related activities. Management states a going concern material uncertainty exists and further financing or strategic activities will be required to fund development beyond current expectations.